Focus on Immunotherapy
Volume 3, Issue 12.1
This special edition features a closer look at immunotherapy, including the challenges and obstacles of clinical trials, the state of CAR T-cell therapy, and immunotherapies in the development pipeline.
Table of Contents
Newly Approved Drugs
The Year in FDA Approvals
The excitement over immunotherapy for cancer treatment shows no signs of waning, with several agents approved by the U.S. Food and Drug Administration (FDA)...
In the Pipeline
The Immunotherapy Pipeline
Below is a partial list of immunotherapeutic agents under investigation for the treatment of malignant and non-malignant hematologic conditions, including monoclonal antibodies, immune checkpoint...
Features
Mining the “Gold Rush” of Immunotherapy Clinical Trials
Immunotherapy has the potential to revolutionize cancer treatment, but as the number of immunotherapy clinical trials continues to grow, so do the challenges and...
Entering A New Era of Immunotherapy
On August 30, 2017, the FDA approved the first gene therapy in the United States: Tisagenlecleucel (Kymriah, Novartis) is a CD19-directed CAR T-cell therapy...
